Business Segments Charles River Laboratories International, Inc.

Equities

Market Closed - Nyse Other stock markets 21:00:02 10/04/2026 BST			5-day change	1st Jan Change
175.65 ^USD	+0.06%		+1.01%	-11.95%

04-08	Baird Raises Price Target on Charles River Laboratories International to $200 From $197, Maintains Outperform Rating	MT
03-31	AI-led selloff in contract research firms may be misjudging disruption risk	RE

Breakdown by Business Segment (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
Life Sciences Tools and Services
Discovery and Safety Assessment (DSA)	2.11B	2.45B	2.62B	2.45B	2.4B
CAPEX	-101M	-190M	-205M	-128M	-133M
D&A	177M	179M	175M	191M	174M
Operating Income	407M	533M	606M	443M	425M
Research Models and Services (RMS)	690M	739M	792M	829M	846M
CAPEX	-61.19M	-44.14M	-52.82M	-64.13M	-38.84M
D&A	39.12M	49.27M	55.57M	73.81M	81.08M
Operating Income	167M	160M	155M	114M	44.57M
Pharmaceutical Contract Research Organization
Manufacturing Solutions (Manufacturing)	742M	790M	721M	769M	766M
CAPEX	-58.88M	-87.08M	-58.13M	-38.5M	-41.43M
D&A	46.2M	72.95M	79.98M	89.96M	140M
Operating Income	246M	167M	88.33M	-71.45M	-184M
D&A	2.97M	2.18M	3.85M	6.84M	7.99M
Operating Income	-	-209M	-232M	-258M	-260M
Operating Income	-17.68M	-	-	-	-
CAPEX	-7.23M	-3.95M	-2.68M	-1.98M	-5.93M
Operating Income	-2.97M	-	-	-	-
Operating Income	-18.45M	-	-	-	-
Operating Income	-25.37M	-	-	-	-
Operating Income	-92.46M	-	-	-	-
Operating Income	-43.02M	-	-	-	-

Geographical breakdown of sales (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
United States (U.S)	1.93B	2.34B	2.35B	2.24B	2.14B
Total Assets	755M	896M	964M	942M	919M
Europe	1.04B	1.03B	1.08B	1.08B	1.1B
Total Assets	323M	349M	407M	413M	469M
Canada	339M	399M	487M	482M	501M
Total Assets	145M	135M	157M	147M	163M
Asia Pacific	223M	193M	201M	197M	205M
Total Assets	64.86M	82.78M	74.6M	66.05M	61.81M
Other	7.29M	9.96M	16.85M	52.82M	64.86M
Total Assets	2.12M	1.98M	36.1M	36.34M	42.19M
Japan	-	-	-	-	-
Total Assets	-	-	-	-	-